Octapharma launches phase 3 study for pediatric acute-onset neuropsychiatric syndrome

(Yankee Public Relations) Octapharma has launched a phase 3, multicenter superiority study to compare the ef-fectiveness of PANZYGA ® (immune globulin intravenous, human - ifas) 10% Liquid Preparation versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome (PANS).
Source: EurekAlert! - Social and Behavioral Science - Category: International Medicine & Public Health Source Type: news